Propensity score-matched study evaluates adjuvant chemotherapy outcomes in stage I non-small cell lung cancer, highlighting high-risk clinicopathologic features.
Surgical resection is the main treatment for early-stage non-small cell lung cancer (NSCLC), but recurrence remains a concern. Adjuvant chemotherapy has been shown to have survival benefits for resected stage II and III NSCLC, but debate continues regarding its use in stage I NSCLC. High-risk features, such as tumor size and stage, are considered in deciding whether to administer adjuvant chemotherapy.
No takes yet. Share an insight, caveat, or question.
Luan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: